Long Non-Coding PROX1-AS1 Expression Correlates with Renal Cell Carcinoma Metastasis and Aggressiveness

Rudzińska, Magdalena; Czarnecka-Chrebelska, Karolina H.; Kuznetsova, Ekaterina; Maryanchik, Sofya V.; Parodi, Alessandro; Korolev, Dmitry; Potoldykova, Nataliya; Svetikova, Yulia; Vinarov, A Z; Немцова, М. В.; Zamyatnin, Andrey A.

doi:10.3390/ncrna7020025

Cited by 6 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TCONS_00020615 is a novel transcript that is antisense to PROX1. Previous studies indicated that lncRNA PROX1-AS1 is up-regulated and acts as a tumor promoter in a wide range of human tumor types, including lung cancer [ 44 ], renal cell carcinoma [ 45 ], gastric cancer [ 46 ] and ovarian cancer [ 47 ].. However, expression levels of TCONS_00020615 have not been investigated.…”

Section: Discussionmentioning

confidence: 99%

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

Background Small cell lung cancer (SCLC) is a highly lethal malignant tumor. It accounts for approximately 15% of newly diagnosed lung cancers. Long non-coding RNAs (lncRNAs) can regulate gene expression and contribute to tumorigenesis through interactions with microRNAs (miRNAs). However, there are only a few studies reporting the expression profiles of lncRNAs, miRNAs, and mRNAs in SCLC. Also, the role of differentially expressed lncRNAs, miRNAs, and mRNAs in relation to competitive endogenous RNAs (ceRNA) network in SCLC remain unclear. Results In the present study, we first performed next generation sequencing (NGS) with six pairs of SCLC tumors and adjacent non-cancerous tissues obtained from SCLC patients. Overall, 29 lncRNAs, 48 miRNAs, and 510 mRNAs were found to be differentially expressed in SCLC samples (|log2[fold change] |> 1; P < 0.05). Bioinformatics analysis was performed to predict and construct a lncRNA-miRNA-mRNA ceRNA network, which included 9 lncRNAs, 11 miRNAs, and 392 mRNAs. Four up-regulated lncRNAs and related mRNAs in the ceRNA regulatory pathways were selected and validated by quantitative PCR. In addition, we examined the role of the most upregulated lncRNA, TCONS_00020615, in SCLC cells. We found that TCONS_00020615 may regulate SCLC tumorigenesis through the TCONS_00020615–hsa-miR-26b-5p–TPD52 pathway. Conclusions Our study provided the comprehensive analysis of the expression profiles of lncRNAs, miRNAs, and mRNAs of SCLC tumors and adjacent non-cancerous tissues. We constructed the ceRNA networks which may provide new evidence for the underlying regulatory mechanism of SCLC. We also found that the lncRNA TCONS_00020615 may regulate the carcinogenesis of SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…TCONS_00020615 is a novel transcript that is antisense to PROX1. Previous studies indicated that lncRNA PROX1-AS1 is up-regulated and acts as a tumor promoter in a wide range of human tumor types, including lung cancer [41], renal cell carcinoma [42], gastric Cancer [43], ovarian cancer [44] and prostate cancer [45]. However, expression levels of TCONS_00020615 have not been investigated.…”

Section: Discussionmentioning

confidence: 99%

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

Zhang

Zhou

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Small cell lung cancer (SCLC) is a highly lethal malignant tumor. It accounts for approximately 15% of newly diagnosed lung cancers. Long non-coding RNAs (lncRNAs) can regulate gene expression and contribute to tumorigenesis through interactions with microRNAs (miRNAs). However, there are only a few studies reporting the expression profiles of lncRNAs, miRNAs, and mRNAs in SCLC. Also, the role of differentially expressed lncRNAs, miRNAs, and mRNAs in relation to competitive endogenous RNAs (ceRNA) network in SCLC remain unclear. Results In the present study, we first performed next generation sequencing (NGS) with six pairs of SCLC tumors and adjacent non-cancerous tissues obtained from SCLC patients. Overall, 29 lncRNAs, 48 miRNAs, and 510 mRNAs were found to be differentially expressed in SCLC samples (|log2[fold change] | > 1; P < 0.05). Bioinformatics analysis was performed to predict and construct a lncRNA-miRNA-mRNA ceRNA network, which included 9 lncRNAs, 11 miRNAs, and 392 mRNAs. Four up-regulated lncRNAs and related mRNAs in the ceRNA regulatory pathways were selected and validated by quantitative PCR. In addition, we examined the role of the most upregulated lncRNA, TCONS_00020615, in SCLC cells. We found that TCONS_00020615 may regulate SCLC tumorigenesis through the TCONS_00020615–hsa-miR-26b-5p–TPD52 pathway. Conclusions Taken together, our findings may help identify some potential biomarkers and therapy targets for SCLC. Also, our study may provide new evidence for the underlying regulatory mechanism in SCLC.

show abstract

“…PROX1-AS1 , a natural antisense transcript overlapping the PROX1 gene, is an oncogenic lncRNA that is upregulated in renal and lung cancer and positively correlates with tumor metastasis [ 183 , 184 ]. However, despite these findings, the role of PROX1-AS1 in the regulation of PROX1 during lymphatic vascular development and disease is currently unknown and requires further investigation.…”

Section: Anril and Gas5mentioning

confidence: 99%

The emerging roles of long noncoding RNAs in lymphatic vascular development and disease

Ivanov

Samuilova

Zamyatnin

2023

Cell. Mol. Life Sci.

Self Cite

View full text Add to dashboard Cite

Recent advances in RNA sequencing technologies helped uncover what was once uncharted territory in the human genome—the complex and versatile world of long noncoding RNAs (lncRNAs). Previously thought of as merely transcriptional “noise”, lncRNAs have now emerged as essential regulators of gene expression networks controlling development, homeostasis and disease progression. The regulatory functions of lncRNAs are broad and diverse, and the underlying molecular mechanisms are highly variable, acting at the transcriptional, post-transcriptional, translational, and post-translational levels. In recent years, evidence has accumulated to support the important role of lncRNAs in the development and functioning of the lymphatic vasculature and associated pathological processes such as tumor-induced lymphangiogenesis and cancer metastasis. In this review, we summarize the current knowledge on the role of lncRNAs in regulating the key genes and pathways involved in lymphatic vascular development and disease. Furthermore, we discuss the potential of lncRNAs as novel therapeutic targets and outline possible strategies for the development of lncRNA-based therapeutics to treat diseases of the lymphatic system.

show abstract

Long Non-Coding PROX1-AS1 Expression Correlates with Renal Cell Carcinoma Metastasis and Aggressiveness

Cited by 6 publications

References 56 publications

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer

The emerging roles of long noncoding RNAs in lymphatic vascular development and disease

Contact Info

Product

Resources

About